Kathryn E. Falberg, Director at Arcus Biosciences, Inc. (RCUS), bought 54,130 shares at $7.99 ($435K) on 2019-06-07, disclosed to the SEC on 2019-06-11.
Open-market purchase of $435k RCUS by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.99 | 22,065 | $176K | 40.5% |
| 2 | $7.99 | 22,065 | $176K | 40.5% |
| 3 | $8.25 | 10,000 | $83K | 19.0% |
| Total | $8.04 avg | 54,130 | $435K | 100% |
| Filing → |
| TTD | SELL | 2024-03-12 | $16.9M | — | Filing → |
| NUVB | BUY | 2022-12-05 | $789K | — | Filing → |
| TTD | SELL | 2021-11-23 | $32.5M | — | Filing → |